JP7688690B2 - ピリミジン系化合物の塩、結晶形およびその調製方法 - Google Patents

ピリミジン系化合物の塩、結晶形およびその調製方法 Download PDF

Info

Publication number
JP7688690B2
JP7688690B2 JP2023503101A JP2023503101A JP7688690B2 JP 7688690 B2 JP7688690 B2 JP 7688690B2 JP 2023503101 A JP2023503101 A JP 2023503101A JP 2023503101 A JP2023503101 A JP 2023503101A JP 7688690 B2 JP7688690 B2 JP 7688690B2
Authority
JP
Japan
Prior art keywords
compound
crystalline form
salt
fumarate
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023503101A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535361A (ja
JP2023535361A5 (https=
Inventor
ゴン，ヂァン
リー，ホンミン
イー，シードン
リー，ロン
ワン，ティアンミン
チェン，ピンユン
ヤン，チェンシー
ワン，タオ
ソン，ヤオヤオ
ヂョウ，ジァンフェン
リァン，ユーフォン
チェン，ヂョンフイ
ティアン，チアン
ソン，ホンメイ
シュ，トントン
ワン，ジンイー
Original Assignee
スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド filed Critical スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド
Publication of JP2023535361A publication Critical patent/JP2023535361A/ja
Publication of JP2023535361A5 publication Critical patent/JP2023535361A5/ja
Application granted granted Critical
Publication of JP7688690B2 publication Critical patent/JP7688690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023503101A 2020-07-28 2021-07-23 ピリミジン系化合物の塩、結晶形およびその調製方法 Active JP7688690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010737039 2020-07-28
CN202010737039.7 2020-07-28
PCT/CN2021/108032 WO2022022398A1 (zh) 2020-07-28 2021-07-23 一种嘧啶类化合物的盐和晶型及其制备方法

Publications (3)

Publication Number Publication Date
JP2023535361A JP2023535361A (ja) 2023-08-17
JP2023535361A5 JP2023535361A5 (https=) 2024-07-29
JP7688690B2 true JP7688690B2 (ja) 2025-06-04

Family

ID=80037147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503101A Active JP7688690B2 (ja) 2020-07-28 2021-07-23 ピリミジン系化合物の塩、結晶形およびその調製方法

Country Status (7)

Country Link
US (1) US20230295174A1 (https=)
EP (1) EP4190781A4 (https=)
JP (1) JP7688690B2 (https=)
KR (1) KR20230044358A (https=)
CN (1) CN115702154A (https=)
BR (1) BR112023000065A2 (https=)
WO (1) WO2022022398A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120897743A (zh) * 2023-05-19 2025-11-04 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与ret基因改变相关疾病的用途和方法
WO2026017002A1 (zh) * 2024-07-16 2026-01-22 四川科伦博泰生物医药股份有限公司 以杂环化合物为活性成分的药物组合物、其制备方法及用途
GB202410599D0 (en) 2024-07-19 2024-09-04 Ellipses Pharma Ltd Therapeutics useful synergistic combinations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111285882A (zh) 2018-12-07 2020-06-16 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
WO2020168939A1 (zh) 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途
WO2022199503A1 (zh) 2021-03-24 2022-09-29 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525422A (ja) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
BR112018000808A2 (pt) * 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
WO2018136661A1 (en) * 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
WO2020114388A1 (zh) * 2018-12-06 2020-06-11 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111285882A (zh) 2018-12-07 2020-06-16 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
WO2020168939A1 (zh) 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 杂环化合物、包含其的药物组合物及其制备方法和用途
WO2022199503A1 (zh) 2021-03-24 2022-09-29 四川科伦博泰生物医药股份有限公司 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法

Also Published As

Publication number Publication date
JP2023535361A (ja) 2023-08-17
KR20230044358A (ko) 2023-04-04
CN115702154A (zh) 2023-02-14
EP4190781A4 (en) 2023-12-27
WO2022022398A1 (zh) 2022-02-03
BR112023000065A2 (pt) 2023-01-31
US20230295174A1 (en) 2023-09-21
EP4190781A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
AU2020220512B2 (en) FGFR inhibitor compound in solid form and preparation method therefor
JP6986032B2 (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
KR101787784B1 (ko) 3－（2,6―디클로로―3,5―디메톡시―페닐）－1－｛6－［4－（4－에틸－피페라진－1－일）－페닐아미노］－피리미딘－4－일｝－1－메틸－우레아의 결정질 형태 및 그의 염
JP7688690B2 (ja) ピリミジン系化合物の塩、結晶形およびその調製方法
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
CN105377835B (zh) 酪氨酸蛋白激酶调节剂及其应用方法
US11629153B2 (en) Forms and compositions of a MK2 inhibitor
CN115175902A (zh) 一类用作激酶抑制剂的化合物及其应用
JP2025094218A (ja) Ｊａｋ２阻害剤の結晶形態
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
KR20250130412A (ko) 화합물 a의 염과 결정형, 및 그 제조 방법과 용도
JP2023536892A (ja) Ｊａｋ阻害剤化合物及びその使用
JP6974618B2 (ja) Ｆｇｆｒ及びｖｅｇｆｒ阻害剤としての化合物の塩形態、結晶形およびその製造方法
WO2019096112A1 (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
WO2021063335A1 (zh) Erk1/2蛋白激酶抑制剂及其用途
CN114026088A (zh) Jak2抑制剂的结晶形式
US20240287045A1 (en) Crystal form of pyrimidine derivative and preparation method therefor
CN115397827B (zh) Fgfr4抑制剂的盐型、晶型及其用途
CN117800954A (zh) 杂环化合物及其应用
CN108430987A (zh) Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
JP2023543080A (ja) ピロロ複素環系誘導体の結晶及びその製造方法
HK40083712A (en) Salt and crystal form of pyrimidine compound, and preparation methods therefor
JP2023531078A (ja) 化合物の結晶形態
CN114075135B (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
WO2020191283A1 (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250501

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250523

R150 Certificate of patent or registration of utility model

Ref document number: 7688690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150